Literature DB >> 16242776

Transforming growth factor-beta1 inhibits all-trans retinoic acid-induced apoptosis.

Karel Soucek1, Jirí Pacherník, Lukás Kubala, Jan Vondrácek, Jirina Hofmanová, Alois Kozubík.   

Abstract

The interaction between retinoids and transforming growth factor-beta1 (TGF-beta1) leading to regulation of proliferation, differentiation and apoptosis is not still fully understood. In this study, we demonstrated that a combination treatment with all-trans retinoic acid (ATRA) and TGF-beta1 led to the enhancement of ATRA-induced suppression of cell proliferation, which is accompanied by inhibition of ATRA-induced apoptosis in human leukemia HL-60 cells. This effect was preceded by the arrest of cells in G0/G1 cell cycle phase linked with pRb protein dephosphorylation, continuous accumulation of p21 and transiently increased level of p27, inhibitors of cyclin-dependent kinases. Inhibition of ATRA-induced apoptosis by TGF-beta1 was associated with an increased level of Mcl-1 protein, an anti-apoptotic member of Bcl-2 family, but not with inhibition of mitochondrial membrane depolarization. Levels of other Bcl-2 family proteins (Bcl-2, Bcl-X(L), Bad, Bak, Bax) were unaffected by simultaneous ATRA and TGF-beta1 treatment, when compared to ATRA alone. Upregulation of c-FLIP(L) protein, an inhibitor of apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), correspond with inhibition of ATRA-induced (autocrine TRAIL-mediated) caspase-8 activation and apoptosis. These results suggest that apoptosis inhibition associated with proliferation block could depend on modulation of the TRAIL apoptotic pathway and regulation of the Mcl-1 protein level. In summary, we demonstrate that the balance of processes leading to regulation of proliferation and differentiation of myeloid cells can modulate cell sensitivity to apoptosis-inducing stimuli.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16242776     DOI: 10.1016/j.leukres.2005.09.007

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  7 in total

1.  TGF-β(1) in retinal ganglion cells in rats with chronic ocular hypertension: its expression and anti-apoptotic effect.

Authors:  Yong-Jian Tao; Dian-Wen Gao; Miao Yu
Journal:  Int J Ophthalmol       Date:  2011-08-18       Impact factor: 1.779

Review 2.  Retinoid and TGF-β families: crosstalk in development, neoplasia, immunity, and tissue repair.

Authors:  Qihe Xu; Jeffrey B Kopp
Journal:  Semin Nephrol       Date:  2012-05       Impact factor: 5.299

3.  TRAIL and vitamins: opting for keys to castle of cancer proteome instead of open sesame.

Authors:  Ammad Ahmad Farooqi; Shahzad Bhatti; Muhammad Ismail
Journal:  Cancer Cell Int       Date:  2012-06-06       Impact factor: 5.722

4.  Synthetic Diphenylacetylene-Based Retinoids Induce DNA Damage in Chinese Hamster Ovary Cells without Altering Viability.

Authors:  Lina Hudhud; David R Chisholm; Andrew Whiting; Anita Steib; Krisztina Pohóczky; Angéla Kecskés; Éva Szőke; Zsuzsanna Helyes
Journal:  Molecules       Date:  2022-02-01       Impact factor: 4.411

5.  Dynamic Monitoring of Cellular Remodeling Induced by the Transforming Growth Factor-β1.

Authors:  Andrea Staršíchová; Lukáš Kubala; Eva Lincová; Zuzana Pernicová; Alois Kozubík; Karel Souček
Journal:  Biol Proced Online       Date:  2009-09-12       Impact factor: 3.244

6.  12-O-Tetradecanoylphorbol-13-acetate increases cardiomyogenesis through PKC/ERK signaling.

Authors:  Katarzyna Anna Radaszkiewicz; Deborah Beckerová; Lucie Woloszczuková; Tomasz Witold Radaszkiewicz; Petra Lesáková; Olga Vondálová Blanářová; Lukáš Kubala; Petr Humpolíček; Jiří Pachernik
Journal:  Sci Rep       Date:  2020-09-28       Impact factor: 4.379

7.  Loss of TG-Interacting Factor 1 decreases survival in mouse models of myeloid leukaemia.

Authors:  Ling Yan; Utpal P Davé; Michael Engel; Stephen J Brandt; Rizwan Hamid
Journal:  J Cell Mol Med       Date:  2020-10-15       Impact factor: 5.295

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.